AbbVie's CONSTELLA Receives Health Canada Approval for Treating Childhood Constipation
Portfolio Pulse from Benzinga Newsdesk
AbbVie has received Health Canada approval for CONSTELLA, a treatment for functional constipation in children aged 6 to 17. This marks the first approved prescription therapy for this condition in Canada, based on successful Phase 3 trial results.
September 10, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie has received Health Canada approval for CONSTELLA, a treatment for functional constipation in children aged 6 to 17. This approval could enhance AbbVie's market presence in Canada and potentially boost sales.
The approval of CONSTELLA by Health Canada is significant as it is the first approved prescription therapy for functional constipation in children in Canada. This could lead to increased sales and market presence for AbbVie in the Canadian market, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90